PO.CH02.02 · 化学
癌前病变和结直肠癌患者粪便宏蛋白质组的全面研究
Comprehensive investigation of stool metaproteomes among patients with precancerous lesions and colorectal cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:结直肠癌(CRC)是美国第二致命的癌症;CRC筛查的大部分益处来自对晚期癌前病变(APLs)的检测。为提高非侵入性粪便检测对APL的敏感性,我们在无癌对照(CTRL)、APL和CRC患者的粪便宏蛋白质组(宿主和肠道微生物组来源的蛋白)中寻找新的APL特征。由于肠道菌群失调与CRC起始相关,我们还检查了差异表达蛋白(DEPs)的微生物来源。
方法:对存档的粪便上清液进行质谱分析(n=63名患者;15名CTRL,32名APL[16例腺瘤和16例无蒂锯齿状病变],16名CRC)。应用分段和数据库富集策略进行肽谱匹配。将微生物和人源蛋白与整合基因目录(IGC)和UniProt人类参考蛋白质组进行搜索。使用P<0.05和倍数变化≥1.5的阈值识别DEPs。使用REVIGO网络服务器对人类DEPs进行通路注释,而使用KEGG自动注释服务器(KAAS)对肠道微生物DEPs进行功能分类。为评估微生物DEPs的分类学分布,使用BLASTP将序列与NCBI非冗余数据库比对。
结果:质谱检测到879个人类蛋白和32,514个微生物组来源蛋白。当将检测限制为存在于≥75%患者中的蛋白时,仅剩117个人类蛋白和204个微生物蛋白。在CTRL、APL和CRC组中分别检测到17(4,875)、288(9,638)和63(3,053)个独特的人类(微生物)蛋白。当蛋白存在截止值设为>30%患者时,在CRC + APL vs CTRL比较中检测到52个DEPs(13个人类[11个上调,2个下调],39个微生物[28个上调,11个下调])。与上调人类DEPs相关的一些通路包括:炎症反应、对铁的细胞反应和内皮细胞迁移。上调最多的微生物DEPs来自Phocaeicola、Lachnospiraceae和Oscillospiraceae属。下调最多的微生物DEPs属于Bacteroides、Eubacterium、Agathobacter、Coprococcus和Blautia属。
结论:这项工作突出了粪便蛋白质组的生物学多样性和分子异质性。我们识别出几种可将APLs和早期CRC与对照区分开的宿主和微生物蛋白标志物。这些结果为未来的验证研究奠定了基础,这些研究对于在将这些蛋白生物标志物整合到非侵入性粪便检测之前确定其临床效用是必要的。
查看英文原文 English abstract
INTRODUCTION: Colorectal cancer (CRC) is the 2nd most fatal cancer in the U.S.; most benefits of CRC screening are from detection of advanced pre-cancerous lesions (APLs). With a goal to improve non-invasive stool test APL sensitivity, we sought novel APL signatures in stool metaproteomes (host- and gut microbiome-derived proteins) among cancer-free controls (CTRL), APL, and CRC patients. Since dysbiosis in gut microbiota is associated with CRC initiation, we also examined the microbial source of differentially expressed proteins (DEPs).
METHODS: Mass spectrometry was performed on archival stool supernatants (n=63 patients; 15 CTRL, 32 APL [16 adenomas & 16 sessile serrated lesions], 16 CRC). A sectioning and database-enrichment strategy was applied for peptide-spectrum matching. Microbial and human-derived proteins were searched against the Integrated Gene Catalogue (IGC) and UniProt human reference proteome. DEPs were identified using thresholds of P < 0.05 and fold-change ≥ 1.5. Pathway annotation of human DEPs was performed with the REVIGO webserver, while gut microbial DEPs were functionally categorized using the KEGG Automatic Annotation Server (KAAS). To assess the taxonomic distribution of microbial DEPs, sequences were aligned against the NCBI non-redundant database using BLASTP.
RESULTS: Mass spectrometry detected 879 human and 32,514 microbiome-derived proteins. When limiting detection to proteins present in ≥ 75% of patients, only 117 human and 204 microbial proteins remained. There were 17 (4,875), 288 (9,638), and 63 (3,053) unique human (microbial) proteins detected in CTRL, APL, and CRC groups, respectively. When the protein presence cutoff was set at >30% of patients, there were 52 (13 human [11 upregulated, 2 downregulated], 39 microbial [28 upregulated, 11 downregulated]) DEPs detected for the CRC + APL vs CTRL comparison. Some pathways associated with upregulated human DEPs included: inflammatory response, cellular response to iron, and endothelial cell migration. The top upregulated microbial DEPs were derived from the Phocaeicola, Lachnospiraceae, and Oscillospiraceae genera. The top downregulated microbial DEPs belonged to the Bacteroides, Eubacterium, Agathobacter, Coprococcus, and Blautia genera.
CONCLUSION: This work highlights the biological diversity and molecular heterogeneity of the stool proteome. We identified several host and microbial protein markers that differentiate APLs and early CRC from controls. These results provide a foundation for future validation studies, which are necessary to determine the clinical utility of these protein biomarkers prior to their integration into a noninvasive stool test.
利益披露 Disclosure
E. J. Northrop-Albrecht, None..
V. K. Gupta, None.
W. R. Taylor,
Exact Sciences Patent, Other Intellectual Property.
J. P. Sinnwell, None.
D. W. Mahoney,
Exact Sciences Patent, Other Intellectual Property.
P. H. Foote, None..
K. N. Burger, None..
J. Sung, None.
J. B. Kisiel,
Exact Sciences ), Patent, Other Intellectual Property.